PDF(Pubmed)
Abstract：
UNASSIGNED: Biologics like growth factors, stem cells, and platelet-rich plasma show potential in stimulating cartilage regrowth and reducing inflammation. By synthesizing preclinical and clinical studies, this study offers insights into how these biologics work and their effectiveness in treating knee osteoarthritis.
UNASSIGNED: Twenty-four participants with knee osteoarthritis (Kellgren - Lawrence grade II or III) were enrolled after obtaining consent. They received three doses of 2 ml intraarticular platelet-rich plasma at 1 month intervals. The clinical assessment involved the oxford knee score (OKS) and visual analogue scale (VAS) for pain on Days 0, 90, and 180. Ultrasound measured femoral and trochlear cartilage thickness pre- (Day 0) and post-PRP (Day 90-180).
UNASSIGNED: Before treatment, the average pain score was 7.2 (p = 1.03). On Day 90 post-PRP, it decreased to 5 (p = 0.81), and by Day 180, it further reduced to 4.5 (p = 0.97). The initial total OKS was 33.5 (p = 1.76), which increased to 36 (p = 1.71) on Day 90 and 38.5 (p = 1.89) on Day 180. The femoral and trochlear cartilage thickness also showed improvement from baseline (0.92) to Day 90 (0.96) and Day 180 (1.01), indicating significant cartilage healing post-PRP administration.
UNASSIGNED: Our study highlights the probability of PRP in treating knee OA, highlighting their ability to alleviate symptoms, enhance joint function, and promote articular cartilage regeneration.
UNASSIGNED: Twenty-four participants with knee osteoarthritis (Kellgren - Lawrence grade II or III) were enrolled after obtaining consent. They received three doses of 2 ml intraarticular platelet-rich plasma at 1 month intervals. The clinical assessment involved the oxford knee score (OKS) and visual analogue scale (VAS) for pain on Days 0, 90, and 180. Ultrasound measured femoral and trochlear cartilage thickness pre- (Day 0) and post-PRP (Day 90-180).
UNASSIGNED: Before treatment, the average pain score was 7.2 (p = 1.03). On Day 90 post-PRP, it decreased to 5 (p = 0.81), and by Day 180, it further reduced to 4.5 (p = 0.97). The initial total OKS was 33.5 (p = 1.76), which increased to 36 (p = 1.71) on Day 90 and 38.5 (p = 1.89) on Day 180. The femoral and trochlear cartilage thickness also showed improvement from baseline (0.92) to Day 90 (0.96) and Day 180 (1.01), indicating significant cartilage healing post-PRP administration.
UNASSIGNED: Our study highlights the probability of PRP in treating knee OA, highlighting their ability to alleviate symptoms, enhance joint function, and promote articular cartilage regeneration.
摘要：
■生长因子等生物制品，干细胞,和富含血小板的血浆显示出刺激软骨再生和减少炎症的潜力。通过综合临床前和临床研究，这项研究提供了有关这些生物制剂如何起作用及其治疗膝骨关节炎的有效性的见解。
■24名膝骨关节炎（Kellgren-LawrenceII级或III级）参与者在获得同意后被纳入。他们每隔1个月接受三次剂量的2ml关节内富血小板血浆。临床评估涉及第0、90和180天疼痛的牛津膝关节评分(OKS)和视觉模拟评分(VAS)。超声测量PRP前(第0天)和后(第90-180天)股骨和滑车软骨厚度。
■治疗前，平均疼痛评分为7.2分(p=1.03).在PRP后的第90天，它减少到5（p=0.81），到第180天，它进一步降低到4.5（p=0.97）。初始总OKS为33.5（p=1.76），在第90天增加到36（p=1.71），在第180天增加到38.5（p=1.89）。股骨和滑车软骨厚度也显示从基线（0.92）到第90天（0.96）和第180天（1.01）的改善，表明PRP给药后软骨愈合显著。
■我们的研究强调了PRP治疗膝关节OA的可能性，强调他们缓解症状的能力，增强关节功能，促进关节软骨再生。
■24名膝骨关节炎（Kellgren-LawrenceII级或III级）参与者在获得同意后被纳入。他们每隔1个月接受三次剂量的2ml关节内富血小板血浆。临床评估涉及第0、90和180天疼痛的牛津膝关节评分(OKS)和视觉模拟评分(VAS)。超声测量PRP前(第0天)和后(第90-180天)股骨和滑车软骨厚度。
■治疗前，平均疼痛评分为7.2分(p=1.03).在PRP后的第90天，它减少到5（p=0.81），到第180天，它进一步降低到4.5（p=0.97）。初始总OKS为33.5（p=1.76），在第90天增加到36（p=1.71），在第180天增加到38.5（p=1.89）。股骨和滑车软骨厚度也显示从基线（0.92）到第90天（0.96）和第180天（1.01）的改善，表明PRP给药后软骨愈合显著。
■我们的研究强调了PRP治疗膝关节OA的可能性，强调他们缓解症状的能力，增强关节功能，促进关节软骨再生。
